



Endoscopic intraductal radiofrequency ablation for extrahepatic cholangiocarcinoma: An update (2023)

Tadahisa Inoue, Masashi Yoneda

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A
Grade B (Very good): B
Grade C (Good): 0
Grade D (Fair): D
Grade E (Poor): 0

P-Reviewer: Bredt LC, Brazil; Ricci AD, Italy

Received: December 27, 2022

Peer-review started: December 27, 2022

First decision: January 17, 2023

Revised: February 15, 2023

Accepted: May 12, 2023

Article in press: May 12, 2023

Published online: June 16, 2023



Tadahisa Inoue, Masashi Yoneda, Department of Gastroenterology, Aichi Medical University, Nagakute 480-1195, Aichi, Japan

Corresponding author: Tadahisa Inoue, MD, PhD, Associate Professor, Department of Gastroenterology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute 480-1195, Aichi, Japan. tinoue-tag@umin.ac.jp

Abstract

Recently, endoscopic intraductal radiofrequency ablation (ID-RFA) has attracted attention as a local treatment method for malignant biliary obstruction (MBO). ID-RFA causes coagulative necrosis of the tumor tissue in the stricture and induces exfoliation. Its effects are expected to extend the patency period of biliary stents and prolong the survival period. Evidence for extrahepatic cholangiocarcinoma (eCCA) is gradually accumulating, and some reports show significant therapeutic effects in eCCA patients without distant metastasis. However, it is still far from an established treatment technique, and many unsolved problems remain. Therefore, when performing ID-RFA in clinical practice, it is necessary to understand and grasp the current evidence well and to operate appropriately for the true benefit of the patients. This paper reviews the current status, issues, and prospects of endoscopic ID-RFA for MBO, especially for eCCA.

Key Words: Intraductal radiofrequency ablation; Cholangiocarcinoma; Biliary tract; Stents; Endoscopy

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Intraductal radiofrequency ablation can be a useful option as a local therapy for malignant biliary obstruction, but there are still many unclear points. Although increasing reports suggest its usefulness, mainly for extrahepatic cholangiocarcinoma without distant metastasis, it is still far from being a standard treatment. Additionally, it should be recognized that the currently available ablation catheter could not always provide sufficient ablation in all cases. In addition to accumulating further evidence, it is necessary to establish its usefulness, clarify its indication, and develop an innovative device that can perform appropriate ablation for all lesions.

Citation: Inoue T, Yoneda M. Endoscopic intraductal radiofrequency ablation for extrahepatic cholangiocarcinoma: An update (2023). *World J Gastrointest Endosc* 2023; 15(6): 440-446

URL: <https://www.wjgnet.com/1948-5190/full/v15/i6/440.htm>

DOI: <https://dx.doi.org/10.4253/wjge.v15.i6.440>

INTRODUCTION

Biliary drainage is an indispensable therapeutic technique for treating obstructive jaundice and cholangitis associated with malignant biliary obstruction (MBO). The endoscopic placement of a biliary stent was introduced in the 1980s[1]; owing to its minimal invasiveness and usefulness, it is now the procedure of choice in most cases of MBO. Although there are various types of stents, metal stents (MS) are recommended for unresectable cases because they have a longer patency period than plastic stents (PS)[2]. However, progress in antitumor therapy has resulted in extended survival period of malignant disease with MBO[3,4], and stent occlusion occurs in a relatively large number of cases even when MS is indwelled. Therefore, extending the stent's patency period is required, including changing the drainage strategy.

Against this background, intraductal radiofrequency ablation (ID-RFA) has emerged as a novel local treatment for MBO[5,6]. ID-RFA was introduced to prolong the patency of the stents. Besides, it has been suggested that it is effective in prolonging survival for extrahepatic cholangiocarcinoma (eCCA). Since the prognosis of eCCA is poor and numerous patients are unresectable at the time of diagnosis, ID-RFA has attracted huge attention and has high expectations as a feasible alternative. However, it is difficult to say that ID-RFA has been established because many unsolved problems remain. To effectively benefit patients, ID-RFA in clinical practice requires a thorough understanding of the available evidence and proper operation.

In this paper, we review the current status, issues, and prospects of endoscopic ID-RFA for MBO, particularly for eCCA.

EFFECT OF ID-RFA ON PROLONGING SURVIVAL FOR eCCA

It is considered that ID-RFA can extend the survival period by reducing the tumor burden, a secondary effect by prolonging the patency of the stent, and antitumor immunity[7,8]. Presently, five randomized controlled trials (RCTs)[9-13] of endoscopic ID-RFA have been reported (Table 1). Yang *et al*[9] and Gao *et al*[11] focus on only eCCA patients, while others involve patients with various diseases. The three RCTs with various etiology did not show a survival benefit of ID-RFA, while Yang *et al*[9] showed that the overall mean survival time was significantly longer in the ID-RFA with stent group (13.2 ± 0.6 vs 8.3 ± 0.5 mo; $P < 0.001$) and Gao *et al*[11] reported that the median overall survival was significantly higher in the patients receiving ID-RFA (14.3 vs 9.2 mo; hazard ratio, 0.488; 95% confidence interval, 0.351-0.678; $P < 0.001$). However, caution in interpreting these results is that both studies by Yang *et al*[9] and Gao *et al*[11] included a mixture of locally advanced and distant metastatic diseases, which were not investigated separately. Although there is hope for the abscopal effect, it is questionable whether ID-RFA, which only ablate the bile duct and its surroundings, has the same effect in patients with a distant metastatic lesion that are directly related to life prognosis and those with only locally advanced disease. Xia *et al*[14] reported a retrospective study with many cases of MBO because of various primary diseases and underwent ID-RFA, and stated that the effect of prolonged survival was shown only in eCCA without distant metastasis.

In summarizing the results of the study above, it is said that the effect of ID-RFA on prolonging the survival period for eCCA can be expected; however, that effect may be limited to locally advanced cases. Therefore, in the future, it will be necessary to further examine the relationship between each disease stage and the effectiveness of ID-RFA, especially focusing on the presence or absence of distant metastasis.

COMBINATION OF ID-RFA AND CHEMOTHERAPY FOR eCCA

Chemotherapy is the current standard treatment for unresectable eCCA[15]. However, the previous RCT by Yang *et al*[9] excluded patients who underwent chemotherapy, and the study by Gao *et al*[11] included only a minimal number of patients who underwent chemotherapy. Therefore, when performing ID-RFA in clinical practice, it is necessary to grasp another evidence of ID-RFA when combined with chemotherapy.

Table 1 Randomized controlled trials of endoscopic intraductal radiofrequency ablation for malignant biliary obstruction

Ref.	No. of patients		Etiology	Location	ID-RFA catheter	ID-RFA setting	Stent type	No. of ID-RFA applications	Stent patency period (median/mean)			Survival period (median/mean)			Adverse event rate		
	RFA + stent	Stent							ID-RFA + stent	Stent	P value	ID-RFA + stent	Stent	P value	ID-RFA + stent	Stent	P value
Yang <i>et al</i> [9], 2018	32	33	Cholangiocarcinoma	Distal, hilar	Habib	7-10W; 90s	PS	Every 3 m ^a	6.8 m ^b	3.4 m ^b	0.02	13.2 m	8.3 m	< 0.001	6.3%	9.1%	0.67
Kang <i>et al</i> [10], 2021 ^c	24	24	Cholangiocarcinoma, pancreatic cancer, other	Distal, Hilar	ELRA	7W/10W; 120s; 80°C	UMS	1	132 d	116 d	0.440	244 m	180 m	0.281	4.2%	12.5%	0.609
Gao <i>et al</i> [11], 2021	87	87	Cholangiocarcinoma ^e	Distal, hilar	Habib	7-10W; 90s	PS	2	3.7 m	4.1 m	0.674	14.3 m	9.2 m	< 0.001	27.6% (early event)	19.5% (early event)	0.211
Kang <i>et al</i> [12], 2022	15	15	Cholangiocarcinoma, gallbladder cancer	Hilar	ELRA	7W; 60-120s; 80°C	UMS	1-2	178 d	122 d	0.154	230 d	144 d	0.643	NA	NA	NS
Albers <i>et al</i> [13], 2022	42	44	Cholangiocarcinoma, pancreatic cancer, other	Distal, Hilar	Habib	10W; 90s	UMS	1	NA ^d	NA ^d	NA ^d	NA ^d	NA ^d	NA ^d	10.5%	2.3%	P = 0.18

^aID-RFA was repeated if the bile duct wall thickness was > 6 mm by intraductal ultrasonography every 3 mo.

^bStent replacement was performed every 3 mo even if it was not occluded.

^cCases of percutaneous approaches were also included.

^dCases of ampullary cancer were also included.

^eStent patency and overall survival rates after 3 and 6 mo did not differ significantly between groups.

ID-RFA: Intraductal radiofrequency ablation; PS: Plastic stent; UMS: Uncovered metal stent; NA: Not applicable; NS: Not significant.

There are three reports regarding the combination of chemotherapy and ID-RFA for eCCA[16-18] (Table 2). First, Yang *et al*[16] reported that the median overall survival was longer in patients who underwent ID-RFA and S-1 chemotherapy than in those who underwent only ID-RFA (16.0 *vs* 11.0 mo; $P < 0.001$), showing the additional effect of S-1 chemotherapy in patients who underwent ID-RFA. However, it noted that distant metastatic cases were excluded from this study. Second, Gonzalez-Carmona *et al*[17] conducted a retrospective study on the additional effect of ID-RFA on patients undergoing gemcitabine-based chemotherapy. They showed significantly longer median overall survival in patients with combined ID-RFA and chemotherapy compared to those with only chemotherapy (17.3 *vs* 8.6 mo, $P = 0.004$). On subgroup analysis of this study, longer median overall survival with the combination of ID-RFA and chemotherapy was maintained in patients with the non-metastatic disease (20.9 *vs* 12.4 mo, $P = 0.043$), whereas it disappeared in patients with metastatic disease (15.0 *vs* 8.6 mo, $P = 0.116$). Finally, Inoue *et al*[18] compared patients who underwent ID-RFA with gemcitabine and cisplatin chemotherapy and those with only gemcitabine and cisplatin chemotherapy. The median overall survival was significantly higher in the patients with ID-RFA and chemotherapy (17.1 *vs* 11.3 mo, $P = 0.017$), indicating an additional effect of ID-RFA in patients treated with

Table 2 Comparative studies of endoscopic intraductal radiofrequency ablation with chemotherapy for extrahepatic cholangiocarcinoma

Ref.	Treatment	No. of patients	Location	Metastatic, %	ID-RFA catheter	Stent type	No. of ID-RFA applications	Stent patency period (median)		Progression free survival (median)		Overall survival (median)	
Yang <i>et al</i> [16], 2020	S-1 chemotherapy + ID-RFA	37	Distal, Hilar	0	Habib	PS	3.3 (mean)	6.6 m	$P = 0.014$	12 m	$P < 0.001$	16.0 m	$P < 0.001$
	ID-RFA	38	Distal, Hilar	0	Habib	PS	2.4 (mean)	5.6 m		7 m		11.0 m	
Gonzalez-Carmona <i>et al</i> [17], 2022	GEM-based chemotherapy + ID-RFA	40	Distal, Hilar	37.5	Habib	PS	1-21	NA	NA	12.9 m	$P = 0.045$	17.3 m	$P = 0.004$
	GEM-based chemotherapy	26	Distal, Hilar	50.0	Habib	PS	-	NA		5.7 m		8.6 m	
Inoue <i>et al</i> [18], 2022	GEM with cisplatin + ID-RFA	25	Distal, Hilar	48	Habib	UMS	1.84 (mean)	10.7 m	$P = 0.048$	8.6 m	$P = 0.014$	17.1 m	$P = 0.017$
	GEM with cisplatin	25	Distal, Hilar	60	Habib	UMS	-	5.2 m		5.8 m		11.3 m	

ID-RFA: Intraductal radiofrequency ablation; PS: Plastic stent; GEM: Gemcitabine; NA: Not applicable; UMS: Uncovered metal stent.

gemcitabine and cisplatin. However, like the results of the study by Gonzalez-Carmona *et al*[17], subgroup analysis showed a significant difference in median overall survival in patients without distant metastases (23.1 *vs* 16.6 mo, $P = 0.032$), while no significant difference in patients with distant metastases (11.4 *vs* 8.5 mo, $P = 0.180$).

These results are similar to those reported by Xia *et al*[14]. The effect of ID-RFA, a local treatment, may be limited to locally advanced cases (no distant metastases). Systemic effects, including induction of antitumor immunity, need to be investigated in more detail, the including the mechanism and evidence from basic research.

EFFECT OF ID-RFA ON PROLONGING STENT PATENCY IN eCCA

In the two currently available RCT for eCCA, PS was used. Yang *et al*[9] showed that the mean stent patency was significantly longer in patients combined with ID-RFA (6.8 *vs* 3.4 mo, $P = 0.02$). In contrast, Gao *et al*[11] found that the median stent patency was insignificant with or without ID-RFA (3.7 *vs* 4.1, $P = 0.674$). However, in Yang *et al*'s study, stent replacement was performed every 3 mo, and interpretation is difficult because it was not a pure evaluation of stent patency[9]. The other RCTs, in which patients were not limited to eCCA, used uncovered MS[10,12,13]. They all showed no significant differences in stent patency with or without ID-RFA.

These results suggest that there is currently no strong evidence to support the effectiveness of endoscopic ID-RFA in prolonging stent patency. However, numerous studies, including prospective, retrospective, and percutaneous approaches, have shown that ID-RFA prolongs stent patency, especially when combined with uncovered MS[5,6,19-24]. Therefore, it may be considered promising that ID-RFA prolongs stent patency, but it is not easy to judge its usefulness because there is not enough evidence. In the future, it will be necessary to determine the usefulness of ID-RFA in further studies by strictly standardizing the target disease, the site of stricture, the type of stent to be used, the placement method, and the approach method.

FUTURE PROSPECTS OF ENDOSCOPIC ID-RFA

As previously indicated, a number of reports of ID-RFA in recent years and evidence has accumulated regarding its therapeutic efficacy, especially for eCCA without distant metastasis. However, while robust evidence is lacking, there are still many unresolved issues, such as differences in tumor localization between the hepatic hilum and distal bile duct, the number of ablation applications performed, and so on. Therefore, it is necessary to conduct well-designed clinical studies and further clarify the indications and situations in which ID-RFA is useful. Additionally, in treating hepatocellular carcinoma, it has been suggested that ablation induce systemic immune effects, so combined use with immunotherapy is expected to prolong further survival[25]. Since recent significant advances were made with immunotherapy in the first-line treatment of advanced CCA with the addition of durvalumab to cisplatin-gemcitabine chemotherapy showing a survival benefit[26,27], it is also expected to investigate the additional effect of combining with ID-RFA.

Another problem is that, sometimes, the currently available ID-RFA catheters cannot ablate sufficiently due to their structure[5,28], and it has been pointed out that the portion in contact with the electrode is ablated strongly, resulting in uneven and unstable ablation depth and area[29]. Additionally, it has been suggested that the entire lesion must appropriately ablate to improve stent patency and survival[12,28]. Therefore, to firmly determine the effect of the use of ID-RFA and for the spread of ID-RFA, improvement of the device is essential; the development of a device that can obtain a stable ablation effect in any stricture lesion and appropriately control the ablation range is needed. Although it is still in the animal experiment stage, attempts have also been made to develop a balloon-based ID-RFA catheter that enables regular contact all around[30,31]. This balloon ID-RFA catheter provides a significantly more stable and appropriate ablation range than the conventional ID-RFA catheter[29]. In addition, a system that can perform ablation under real-time observation with cholangioscopy has also appeared[32]. Next-generation ID-RFA devices are expected to enter clinical trials soon, resulting in enhanced treatment outcomes and broader ID-RFA indications.

CONCLUSION

The current issues and prospects of endoscopic ID-RFA were reviewed, focusing on eCCA. ID-RFA can be a useful option as an intrabiliary local therapy, but there are still many unclear points. Although increasing reports suggest its usefulness, mainly for eCCA without distant metastasis, it is still far from being a standard treatment. Additionally, it should be recognized that the existing catheter could not always provide sufficient ablation in all cases. Therefore, in addition to accumulating further evidence, it is necessary to establish its usefulness, clarify its indication, and develop an innovative device that can perform appropriate ablation for all lesions.

FOOTNOTES

Author contributions: Inoue T contributed to conception and design, data acquisition, analysis and interpretation, and drafting and revision of the manuscript; Yoneda M contributed to data interpretation, and revision of the manuscript.

Conflict-of-interest statement: Tadahisa Inoue received honoraria from Boston Scientific Japan and Japan Lifeline Co., Ltd. Masashi Yoneda discloses no financial relationships relevant to this publication.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Japan

ORCID number: Tadahisa Inoue 0000-0003-0718-9099.

S-Editor: Liu JH

L-Editor: A

P-Editor: Fan JR

REFERENCES

- 1 Soehendra N, Reynders-Frederix V. Palliative bile duct drainage - a new endoscopic method of introducing a transpapillary drain. *Endoscopy* 1980; **12**: 8-11 [PMID: 7353562 DOI: 10.1055/s-2007-1021702]
- 2 Almadi MA, Barkun A, Martel M. Plastic vs. Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses. *Am J Gastroenterol* 2017; **112**: 260-273 [PMID: 27845340 DOI: 10.1038/ajg.2016.512]
- 3 Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjuland SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; **369**: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]
- 4 Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 2010; **362**: 1273-1281 [PMID: 20375404 DOI: 10.1056/NEJMoa0908721]
- 5 Inoue T, Yoneda M. Updated evidence on the clinical impact of endoscopic radiofrequency ablation in the treatment of malignant biliary obstruction. *Dig Endosc* 2022; **34**: 345-358 [PMID: 34107114 DOI: 10.1111/den.14059]
- 6 Sofi AA, Khan MA, Das A, Sachdev M, Khuder S, Nawras A, Lee W. Radiofrequency ablation combined with biliary stent placement versus stent placement alone for malignant biliary strictures: a systematic review and meta-analysis. *Gastrointest Endosc* 2018; **87**: 944-951.e1 [PMID: 29108980 DOI: 10.1016/j.gie.2017.10.029]
- 7 Haen SP, Pereira PL, Salih HR, Rammensee HG, Gouttefangeas C. More than just tumor destruction: immunomodulation by thermal ablation of cancer. *Clin Dev Immunol* 2011; **2011**: 160250 [PMID: 22242035 DOI: 10.1155/2011/160250]
- 8 Giardino A, Innamorati G, Ugel S, Perbellini O, Girelli R, Frigerio I, Regi P, Scopelliti F, Butturini G, Paiella S, Bacchion M, Bassi C. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. *Pancreatol* 2017; **17**: 962-966 [PMID: 29037917 DOI: 10.1016/j.pan.2017.09.008]
- 9 Yang J, Wang J, Zhou H, Zhou Y, Wang Y, Jin H, Lou Q, Zhang X. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. *Endoscopy* 2018; **50**: 751-760 [PMID: 29342492 DOI: 10.1055/s-0043-124870]
- 10 Kang H, Chung MJ, Cho IR, Jo JH, Lee HS, Park JY, Park SW, Song SY, Bang S. Efficacy and safety of palliative endobiliary radiofrequency ablation using a novel temperature-controlled catheter for malignant biliary stricture: a single-center prospective randomized phase II TRIAL. *Surg Endosc* 2021; **35**: 63-73 [PMID: 32488654 DOI: 10.1007/s00464-020-07689-z]
- 11 Gao DJ, Yang JF, Ma SR, Wu J, Wang TT, Jin HB, Xia MX, Zhang YC, Shen HZ, Ye X, Zhang XF, Hu B. Endoscopic radiofrequency ablation plus plastic stent placement versus stent placement alone for unresectable extrahepatic biliary cancer: a multicenter randomized controlled trial. *Gastrointest Endosc* 2021; **94**: 91-100.e2 [PMID: 33359435 DOI: 10.1016/j.gie.2020.12.016]
- 12 Kang H, Han SY, Cho JH, Kim EJ, Kim DU, Yang JK, Jeon S, Park G, Lee TH. Efficacy and safety of temperature-controlled intraductal radiofrequency ablation in advanced malignant hilar biliary obstruction: A pilot multicenter randomized comparative trial. *J Hepatobiliary Pancreat Sci* 2022; **29**: 469-478 [PMID: 34800357 DOI: 10.1002/jhbp.1082]
- 13 Albers D, Schmidt A, Schiemer M, Caca K, Wannhoff A, Sauer P, Wiesweg M, Schumacher B, Dechene A. Impact of endobiliary radiofrequency ablation on biliary drainage in patients with malignant biliary strictures treated with uncovered self-expandable metal stents: a randomized controlled multicenter trial. *Gastrointest Endosc* 2022; **96**: 970-979 [PMID: 35667389 DOI: 10.1016/j.gie.2022.05.022]
- 14 Xia MX, Wang SP, Yuan JG, Gao DJ, Ye X, Wang TT, Wu J, Zhou DX, Hu B. Effect of endoscopic radiofrequency ablation on the survival of patients with inoperable malignant biliary strictures: A large cohort study. *J Hepatobiliary Pancreat Sci* 2022; **29**: 693-702 [PMID: 33829657 DOI: 10.1002/jhbp.960]
- 15 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". *Cancer Treat Res Commun* 2021; **27**: 100335 [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335]
- 16 Yang J, Wang J, Zhou H, Wang Y, Huang H, Jin H, Lou Q, Shah RJ, Zhang X. Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone for unresectable extrahepatic cholangiocarcinoma. *Gastrointest Endosc* 2020; **92**: 1204-1212.e1 [PMID: 32437711 DOI: 10.1016/j.gie.2020.04.075]
- 17 Gonzalez-Carmona MA, Möhring C, Mahn R, Zhou T, Bartels A, Sadeghlar F, Bolch M, Vogt A, Kaczmarek DJ, Heling DJ, Dold L, Nattermann J, Branchi V, Matthaei H, Manekeller S, Kalff JC, Strassburg CP, Mohr RU, Weismüller TJ. Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. *Sci Rep* 2022; **12**: 1011 [PMID: 35046437 DOI: 10.1038/s41598-021-04297-2]
- 18 Inoue T, Naitoh I, Kitano R, Ibusuki M, Kobayashi Y, Sumida Y, Nakade Y, Ito K, Yoneda M. Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma. *Curr Oncol* 2022; **29**: 2240-2251 [PMID: 35448156 DOI: 10.3390/curroncol29040182]
- 19 Li TF, Huang GH, Li Z, Hao CF, Ren JZ, Duan XH, Zhang K, Chen C, Han XW, Jiao DC, Zhang MF, Wang YL.

- Percutaneous transhepatic cholangiography and intraductal radiofrequency ablation combined with biliary stent placement for malignant biliary obstruction. *J Vasc Interv Radiol* 2015; **26**: 715-721 [PMID: [25817458](#) DOI: [10.1016/j.jvir.2015.01.037](#)]
- 20 **Wang J**, Zhao L, Zhou C, Gao K, Huang Q, Wei B, Gao J. Percutaneous Intraductal Radiofrequency Ablation Combined with Biliary Stent Placement for Nonresectable Malignant Biliary Obstruction Improves Stent Patency but not Survival. *Medicine (Baltimore)* 2016; **95**: e3329 [PMID: [27082582](#) DOI: [10.1097/MD.00000000000003329](#)]
 - 21 **Wu TT**, Li WM, Li HC, Ao GK, Zheng F, Lin H. Percutaneous Intraductal Radiofrequency Ablation for Extrahepatic Distal Cholangiocarcinoma: A Method for Prolonging Stent Patency and Achieving Better Functional Status and Quality of Life. *Cardiovasc Intervent Radiol* 2017; **40**: 260-269 [PMID: [27743089](#) DOI: [10.1007/s00270-016-1483-2](#)]
 - 22 **Cui W**, Wang Y, Fan W, Lu M, Zhang Y, Yao W, Li J. Comparison of intraluminal radiofrequency ablation and stents vs. stents alone in the management of malignant biliary obstruction. *Int J Hyperthermia* 2017; **33**: 853-861 [PMID: [28540797](#) DOI: [10.1080/02656736.2017.1309580](#)]
 - 23 **Yu T**, Zhang W, Li C, Wang C, Gong G, Wang L, Li G, Chen Y, Wang X. Percutaneous intraductal radiofrequency ablation combined with biliary stent placement for treatment of malignant biliary obstruction. *Abdom Radiol (NY)* 2020; **45**: 3690-3697 [PMID: [32277241](#) DOI: [10.1007/s00261-020-02516-4](#)]
 - 24 **Uyanık SA**, Ögüslü U, Çevik H, Atlı E, Yılmaz B, Gümüş B. Percutaneous endobiliary ablation of malignant biliary strictures with a novel temperature-controlled radiofrequency ablation device. *Diagn Interv Radiol* 2021; **27**: 102-108 [PMID: [33252335](#) DOI: [10.5152/dir.2020.20333](#)]
 - 25 **Chen S**, Zeng X, Su T, Xiao H, Lin M, Peng Z, Peng S, Kuang M. Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective. *Front Immunol* 2022; **13**: 1033000 [PMID: [36505437](#) DOI: [10.3389/fimmu.2022.1033000](#)]
 - 26 **Roth GS**, Neuzillet C, Sarabi M, Edeline J, Malka D, Lièvre A. Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine? *Eur J Cancer* 2023; **179**: 1-14 [PMID: [36463640](#) DOI: [10.1016/j.ejca.2022.11.006](#)]
 - 27 **Rizzo A**, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. *Expert Opin Investig Drugs* 2021; **30**: 343-350 [PMID: [33645367](#) DOI: [10.1080/13543784.2021.1897102](#)]
 - 28 **Inoue T**, Ibusuki M, Kitano R, Kobayashi Y, Ohashi T, Nakade Y, Sumida Y, Ito K, Yoneda M. Endobiliary radiofrequency ablation combined with bilateral metal stent placement for malignant hilar biliary obstruction. *Endoscopy* 2020; **52**: 595-599 [PMID: [32208498](#) DOI: [10.1055/a-1133-4448](#)]
 - 29 **Inoue T**, Ito K, Yoneda M. Novel balloon catheter-based endobiliary radiofrequency ablation system: Ex-vivo experimental study. *Dig Endosc* 2020; **32**: 974-978 [PMID: [31916300](#) DOI: [10.1111/den.13622](#)]
 - 30 **Inoue T**, Yoneda M. Evaluating the tissue effects of balloon-based endobiliary radiofrequency ablation in porcine bile ducts. *Int J Hyperthermia* 2020; **37**: 1383-1385 [PMID: [33327820](#) DOI: [10.1080/02656736.2020.1859627](#)]
 - 31 **Nociarova J**, Novak M, Polak J, Hrudka J, Porubsky S, Koc M, Rosina J, Grebenyuk AN, Sery R, Gurlich R, Hajer J. Development of Radiofrequency Ablation Generator and Balloon-Based Catheter for Microendoluminal Thin-Layer Ablation Therapy Using the Rat Duodenum as a Model of Low-Impedance Tissue. *J Healthc Eng* 2021; **2021**: 9986874 [PMID: [34603652](#) DOI: [10.1155/2021/9986874](#)]
 - 32 **Inoue T**, Kutsumi H, Ibusuki M, Yoneda M. Feasibility of balloon-based endobiliary radiofrequency ablation under cholangioscopy guidance in a swine model. *Sci Rep* 2021; **11**: 14254 [PMID: [34244576](#) DOI: [10.1038/s41598-021-93643-5](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

